FGFR Pathway Inhibition in Gastric Cancer: The Golden Era of an Old Target?

Csongor G. Lengyel; Sadaqat Hussain; Andreas Seeber; Sara Jamil Nidhamalddin; Dario Trapani; Baker S. Habeeb; Essam Elfaham; Syed Ayub Mazher; Fahmi Seid; Shah Z. Khan; Khalid El Bairi; Andrew Odhiambo; Sara C. Altuna; Angelica Petrillo

doi:10.3390/life12010081

FGFR Pathway Inhibition in Gastric Cancer: The Golden Era of an Old Target?

Csongor G. Lengyel, Sadaqat Hussain, Andreas Seeber, Sara Jamil Nidhamalddin, Dario Trapani, Baker S. Habeeb, Essam Elfaham, Syed Ayub Mazher, Fahmi Seid, Shah Z. Khan, Khalid El Bairi, Andrew Odhiambo, Sara C. Altuna, Angelica Petrillo

Research output: Contribution to journal › Review article › peer-review

18 Scopus citations

Abstract

Gastric cancer (GC) is the third leading cause of cancer-associated death worldwide. The majority of patients are diagnosed at an advanced/metastatic stage of disease due to a lack of specific symptoms and lack of screening programs, especially in Western countries. Thus, despite the improvement in GC therapeutic opportunities, the survival is disappointing, and the definition of the optimal treatment is still an unmet need. Novel diagnostic techniques were developed in clinical trials in order to characterize the genetic profile of GCs and new potential molecular pathways, such as the Fibroblast Growth Factor Receptor (FGFR) pathway, were identified in order to improve patient’s survival by using target therapies. The aim of this review is to summarize the role and the impact of FGFR signaling in GC and to provide an overview regarding the potential effectiveness of anti-FGFR agents in GC treatment in the context of precision medicine.

Original language	English (US)
Article number	81
Journal	Life
Volume	12
Issue number	1
DOIs	https://doi.org/10.3390/life12010081
State	Published - Jan 2022

Keywords

Bemarituzumab
FGFR fusions
FGFR inhibitors
Fibroblast growth factor receptors
First line
Next generation sequencing
Precision medicine
Target therapy
Tyrosine kinase inhibitors

ASJC Scopus subject areas

Ecology, Evolution, Behavior and Systematics
General Biochemistry, Genetics and Molecular Biology
Space and Planetary Science
Palaeontology

Access to Document

10.3390/life12010081

Cite this

@article{d178cc98e4124ae0b900a826fefb00af,

title = "FGFR Pathway Inhibition in Gastric Cancer: The Golden Era of an Old Target?",

abstract = "Gastric cancer (GC) is the third leading cause of cancer-associated death worldwide. The majority of patients are diagnosed at an advanced/metastatic stage of disease due to a lack of specific symptoms and lack of screening programs, especially in Western countries. Thus, despite the improvement in GC therapeutic opportunities, the survival is disappointing, and the definition of the optimal treatment is still an unmet need. Novel diagnostic techniques were developed in clinical trials in order to characterize the genetic profile of GCs and new potential molecular pathways, such as the Fibroblast Growth Factor Receptor (FGFR) pathway, were identified in order to improve patient{\textquoteright}s survival by using target therapies. The aim of this review is to summarize the role and the impact of FGFR signaling in GC and to provide an overview regarding the potential effectiveness of anti-FGFR agents in GC treatment in the context of precision medicine.",

keywords = "Bemarituzumab, FGFR fusions, FGFR inhibitors, Fibroblast growth factor receptors, First line, Next generation sequencing, Precision medicine, Target therapy, Tyrosine kinase inhibitors",

author = "Lengyel, {Csongor G.} and Sadaqat Hussain and Andreas Seeber and Nidhamalddin, {Sara Jamil} and Dario Trapani and Habeeb, {Baker S.} and Essam Elfaham and Mazher, {Syed Ayub} and Fahmi Seid and Khan, {Shah Z.} and {El Bairi}, Khalid and Andrew Odhiambo and Altuna, {Sara C.} and Angelica Petrillo",

note = "Publisher Copyright: {\textcopyright} 2022 by the authors. Licensee MDPI, Basel, Switzerland.",

year = "2022",

month = jan,

doi = "10.3390/life12010081",

language = "English (US)",

volume = "12",

journal = "Life",

issn = "0024-3019",

publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",

number = "1",

}

TY - JOUR

T1 - FGFR Pathway Inhibition in Gastric Cancer

T2 - The Golden Era of an Old Target?

AU - Lengyel, Csongor G.

AU - Hussain, Sadaqat

AU - Seeber, Andreas

AU - Nidhamalddin, Sara Jamil

AU - Trapani, Dario

AU - Habeeb, Baker S.

AU - Elfaham, Essam

AU - Mazher, Syed Ayub

AU - Seid, Fahmi

AU - Khan, Shah Z.

AU - El Bairi, Khalid

AU - Odhiambo, Andrew

AU - Altuna, Sara C.

AU - Petrillo, Angelica

PY - 2022/1

Y1 - 2022/1

N2 - Gastric cancer (GC) is the third leading cause of cancer-associated death worldwide. The majority of patients are diagnosed at an advanced/metastatic stage of disease due to a lack of specific symptoms and lack of screening programs, especially in Western countries. Thus, despite the improvement in GC therapeutic opportunities, the survival is disappointing, and the definition of the optimal treatment is still an unmet need. Novel diagnostic techniques were developed in clinical trials in order to characterize the genetic profile of GCs and new potential molecular pathways, such as the Fibroblast Growth Factor Receptor (FGFR) pathway, were identified in order to improve patient’s survival by using target therapies. The aim of this review is to summarize the role and the impact of FGFR signaling in GC and to provide an overview regarding the potential effectiveness of anti-FGFR agents in GC treatment in the context of precision medicine.

AB - Gastric cancer (GC) is the third leading cause of cancer-associated death worldwide. The majority of patients are diagnosed at an advanced/metastatic stage of disease due to a lack of specific symptoms and lack of screening programs, especially in Western countries. Thus, despite the improvement in GC therapeutic opportunities, the survival is disappointing, and the definition of the optimal treatment is still an unmet need. Novel diagnostic techniques were developed in clinical trials in order to characterize the genetic profile of GCs and new potential molecular pathways, such as the Fibroblast Growth Factor Receptor (FGFR) pathway, were identified in order to improve patient’s survival by using target therapies. The aim of this review is to summarize the role and the impact of FGFR signaling in GC and to provide an overview regarding the potential effectiveness of anti-FGFR agents in GC treatment in the context of precision medicine.

KW - Bemarituzumab

KW - FGFR fusions

KW - FGFR inhibitors

KW - Fibroblast growth factor receptors

KW - First line

KW - Next generation sequencing

KW - Precision medicine

KW - Target therapy

KW - Tyrosine kinase inhibitors

UR - http://www.scopus.com/inward/record.url?scp=85122760167&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85122760167&partnerID=8YFLogxK

U2 - 10.3390/life12010081

DO - 10.3390/life12010081

M3 - Review article

C2 - 35054474

AN - SCOPUS:85122760167

SN - 0024-3019

VL - 12

JO - Life

JF - Life

IS - 1

M1 - 81

ER -

FGFR Pathway Inhibition in Gastric Cancer: The Golden Era of an Old Target?

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this